Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
IMSE, TU Munich (Biometry)
WiSP GmbH, Langenfeld (Monitoring and Data Management)
Central study office of the GCLLSG Cologne
Information provided by (Responsible Party):
Stephan Stilgenbauer, University of Ulm
ClinicalTrials.gov Identifier:
NCT01392079
First received: June 28, 2011
Last updated: August 30, 2012
Last verified: August 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2013
  Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)